Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13893
Revised: May 7, 2014
Accepted: June 21, 2014
Published online: October 14, 2014
Processing time: 224 Days and 21.3 Hours
Pancreatic neuroendocrine neoplasms (PNENs) are rare and account for only 2%-4% of all pancreatic neoplasms. All PNENs are potential (neurendocrine tumors PNETs) or overt (neuroendocrine carcinomas PNECs) malignant, but a subset of PNETs is low-risk. Even in case of low-risk PNETs surgical resection is frequently required to treat hormone-related symptoms and to obtain an appropriate pathological diagnosis. Low-risk PNETs in the body and the tail are ideal for minimally-invasive approaches which should be tailored to the individual patient. Generally, surgeons must aim for parenchyma sparing in these cases. In high-risk and malignant PNENs, indications for tumor resection are much wider than for pancreatic adenocarcinoma, in many cases due to the relatively benign tumor biology. Thus, patients with locally advanced and metastatic PNETs may benefit from extensive resection. In experienced hands, even multi-organ resections are accomplished with acceptable perioperative morbidity and mortality rates and are associated with excellent long term survival. However, poorly differentiated neoplasms with high proliferation rates are associated with a dismal prognosis and may frequently only be treated with chemotherapy. The evidence on surgical treatment of PNENs stems from reviews of mostly single-center series and some analyses of nation-wide tumor registries. No randomized trial has been performed to compare surgical and non-surgical therapies in potentially resectable PNEN. Though such a trial would principally be desirable, ethical considerations and the heterogeneity of PNENs preclude realization of such a study. In the current review, we summarize recent advances in the surgical treatment of PNENs.
Core tip: Surgical resection is the only curative treatment for pancreatic neuroendocrine neoplasms (PNENs). Surgical resection should be tailored and parenchyma-preserving whenever possible. Laparoscopic approaches are feasible and safe for pancreatic body and tail lesions. Regional lymph node dissection may prolong disease free survival. Cytoreductive surgery and palliative debulking (> 90%) of PNET liver metastases may extend survival. The most relevant prognostic factors are surgical intervention, tumor differentiation, patient age, and distant metastases.